ライフサイエンスコーパス: cefazolin

1 afcillin) or first-generation cephalosporin (cefazolin).

2 or other drug if the patient was allergic to cefazolin).

3 ntravenous antibiotic prophylaxis, primarily cefazolin.

4 ecifically antistaphylococcal penicillins or cefazolin.

5 tively, for those treated with nafcillin and cefazolin.

6 ains and maintain sterility after removal of cefazolin.

7 incubation at 37 degrees C in the absence of cefazolin.

8 ic acid and a first-generation cephalosporin cefazolin.

9 who receive a beta-lactam antibiotic such as cefazolin.

10 6.7% of outpatients with MSSA were receiving cefazolin.

11 %) patients received definitive therapy with cefazolin.

12 ted with cellular response to the antibiotic Cefazolin.

13 coli cells to penicillin G-streptomycin and cefazolin.

14 BU2 killing compared to decreased killing by cefazolin.

15 potentiated the benefit of prophylaxis with cefazolin.

16 is resistant to ampicillin, ticarcillin, and cefazolin.

17 An intracameral bolus injection of cefazolin (1 mg in 0.1 ml solution) at the conclusion of

18 There were 3 very major errors (all with cefazolin), 1 major error (also with cefazolin), and 26

19 ed and received a single intravenous dose of cefazolin (15 mg/kg) and tobramycin (0.6 mg/kg).

20 r PD-related peritonitis may be adequate for cefazolin (15 to 20 mg/kg); however, tobramycin doses mu

21 e to all antimicrobial agents tested, except cefazolin (20% of isolates were resistant) and cefoxitin

22 CA was lower for ampicillin (80.3%) and cefazolin (77.0%).

23 agent were associated with fewer SSI events (cefazolin: adjusted OR = 0.49; 95% CI, 0.34-0.71; quinol

24 in discontinuation, treatment was changed to cefazolin; all 9 completed treatment with no further obs

25 t intraperitoneal administration of 15 mg/kg cefazolin and 0.6 mg/kg tobramycin.

26 reonam, cefepime, and ceftriaxone, and 1 for cefazolin and ceftazidime).

27 rioperative prophylaxis included vancomycin, cefazolin and micafungin and was adjusted based on perit

28 o other antibiotics, there was resistance to cefazolin and sensitivity to vancomycin in all isolates,

29 ncubation at 28 degrees C in the presence of cefazolin and subsequent incubation at 37 degrees C in t

30 Cefazolin and tobramycin half-lives were markedly differ

31 that of combination therapy using fortified cefazolin and tobramycin in the treatment of moderate ba

32 The disposition of intravenous cefazolin and tobramycin was studied in automated PD (AP

33 05%) observed using the Vitek 2 breakpoints (cefazolin) and 8 VMEs (0.5%) using the CLSI breakpoints

34 ll with cefazolin), 1 major error (also with cefazolin), and 26 minor errors.

35 llenges with cefuroxime axetil, ceftriaxone, cefazolin, and ceftibuten; and group C and D subjects un

36 subjects underwent challenges with cefaclor, cefazolin, and ceftibuten; group B participants underwen

37 solates (49%) were sensitive to cephalothin, cefazolin, and cefuroxime.

38 Nafcillin and cefazolin are considered first-line therapy for most inf

39 t-line MSSA therapies (nafcillin, oxacillin, cefazolin) are generally avoided in the 10% of patients

40 g penicillin-G, amoxicillin, ampicillin, and cefazolin, are protected from beta-lactamase hydrolysis

41 reus strains were exposed to ceftriaxone and cefazolin at concentrations from 0 to 1000 mug/mL under

42 The Raman spectra of cells exposed to Cefazolin at the end of log phase exhibited a different

43 these findings, we recommend that high-dose cefazolin be used for prophylaxis in (sub)normothermic o

44 preoperative intravenous dose of 1000 mg of cefazolin (cefazolin group, n = 228) or sodium chloride

45 Aztreonam, cefazolin, cefepime, and, to a lesser extent, ceftazidim

46 (MICs) of four antimicrobial agents, namely, cefazolin, ceftazidime, cefepime, and doripenem, were de

47 Polymyxin B was studied in combination with cefazolin, ceftriaxone, cefepime, imipenem, gentamicin,

48 A total of 264 isolates were subjected to cefazolin, ceftriaxone, cefotaxime, ceftazidime, cefepim

49 uency (pdf) and cell length of GNB under the cefazolin (CEZ) treatment.

50 ), benzylpenicillin (PEG), cephalexin (CFX), cefazolin (CFL), cefoperazone (CFP), cloxacillin (CLO),

51 Cefazolin (CFZ) and cephapirin (CFP) underwent mainly di

52 P), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ) susceptibilities were <71%.

53 cteriaceae for susceptibility to ampicillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropene

54 36) were similar among patients who received cefazolin compared with patients who received nafcillin

55 e, a single preoperative dose of intravenous cefazolin compared with saline did not reduce the risk o

56 g PS with 10 colony-forming units/mL, only a cefazolin concentration of 1000 mug/mL was able to exert

57 Cefazolin exhibited greater bactericidal effect on S. ep

58 of patients treated with either nafcillin or cefazolin for MSSA infection in the outpatient parentera

59 seven years using prophylactic intracameral cefazolin for the prevention of endophthalmitis in catar

60 cians might consider definitive therapy with cefazolin for these infections.

61 beta-lactam (either nafcillin, oxacillin, or cefazolin) for staphylococcal bacteremia may improve inf

62 d an SSI (14.0%): 30 patients (13.2%) in the cefazolin group vs 36 in the saline group (14.9%) (absol

63 ve intravenous dose of 1000 mg of cefazolin (cefazolin group, n = 228) or sodium chloride (0.9%; sali

64 The hazard ratio for PAD in the nafcillin vs cefazolin groups was 2.81 (95% confidence interval [CI],

65 Patients who received cefazolin had a 37% reduction in 30-day mortality (hazar

66 ge, multicenter study, patients who received cefazolin had a lower risk of mortality and similar odds

67 history excludes anaphylactic features, give cefazolin (Hx-Cefaz); and (3) complete allergy evaluatio

68 ternative cephalosporins (ceftibuten in 101, cefazolin in 96, cefaclor in 82, and cefuroxime axetil a

69 thalmitis reduced from 0.63% to 0.05% with a cefazolin injection.

70 y associated with lower SSI rates, including cefazolin/metronidazole, ciprofloxacin/metronidazole, an

71 or MSSA and received definitive therapy with cefazolin, nafcillin, or oxacillin.

72 was associated with duration of exposure to cefazolin (odds ratio, 10.3; p < or = .006) and to broad

73 ler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cycler : 23.09 +/- 5.6 h; P = 0.001; tobra

74 arkedly different on cycler than off cycler (cefazolin on cycler : 10.67 +/- 4.66 h; cefazolin off cy

75 decreased further for patients who received cefazolin or antistaphylococcal penicillins compared wit

76 MRSA carriers received vancomycin and cefazolin or cefuroxime for perioperative prophylaxis; a

77 rioperative prophylaxis; all others received cefazolin or cefuroxime.

78 microbial resistance over time was observed: cefazolin (P = 0.02), cefotetan (P = 0.006), cephalothin

79 ed treatment course with nafcillin than with cefazolin (PAD rate, 33.8% vs 6.7%; P < .0001).

80 robial metabolite of ceftiofur), ampicillin, cefazolin, penicillin G, oxacillin, cloxacillin, naficil

81 ith wound infections complicating the use of cefazolin prophylaxis in surgery.

82 ge of the 120 wound isolates associated with cefazolin prophylaxis than they did of the 95 isolates a

83 for the beta-lactamase-negative isolate when cefazolin prophylaxis was administered (599 vs. 128 cfu,

84 Model-predicted intraperitoneal cefazolin provides adequate serum and dialysate concentr

85 on between the outer membrane porin nmpC and cefazolin resistance in E. coli.

86 Cefazolin resistance ranged from 17% of A. veronii bioty

87 bilty testing, all Enterococci isolates were cefazolin-resistant.

88 119 patients were treated with nafcillin or cefazolin, respectively.

89 Finally, 1000 mug/mL cefazolin showed no adverse effects on porcine kidney en

90 preoperative antibacterial prophylaxis with cefazolin sodium (or other drug if the patient was aller

91 p A was given combination therapy (fortified cefazolin sodium 5% and tobramycin sulfate) and group B

92 Cefazolin sodium and quinolone in combination with an an

93 titutions A, B, and C were cefoxitin sodium, cefazolin sodium with metronidazole, and ampicillin sodi

94 CN skin testing: if skin test negative, give cefazolin (ST-Cefaz).

95 For the very hydrophilic cefazolin there was little sign of efflux.

96 es of both PAD as well as DEEs compared with cefazolin treatment.

97 Cefazolin use in prophylaxis is a risk factor for BSSA-5

98 This study compared definitive therapy with cefazolin vs nafcillin or oxacillin among patients with

99 The toxicity of cefazolin was assessed by cell viability and caspase act

100 week after blood culture collection, use of cefazolin was associated with a 38% lower risk for hospi

101 o mimic procedural conditions, the effect of cefazolin was determined after exposure of bacteria to 2

102 In vitro assays demonstrated that cefazolin was hydrolyzed faster by BSSA-5 strains than b

103 09 (in whom a 1 mg/0.1 bolus of intracameral cefazolin was instilled).